Charles River Laboratories International (CRL)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Charles River Laboratories International (CRL)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Key Insights
Critical company metrics and information
Share Price
$191.81Market Cap
$9.81 BillionTotal Outstanding Shares
51.14 Million SharesTotal Employees
21,400Dividend
No dividendIPO Date
June 23, 2000SIC Description
Services-commercial Physical & Biological ResearchHomepage
https://www.criver.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
September 29, 2023 to September 28, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-407.35 Million |
| Net Cash Flow, Continuing | $37.33 Million |
| Net Cash Flow | $46.02 Million |
| Net Cash Flow From Operating Activities | $796.16 Million |
| Net Cash Flow From Operating Activities, Continuing | $796.16 Million |
| Net Cash Flow From Financing Activities, Continuing | $-351.48 Million |
| Exchange Gains/Losses | $8.70 Million |
| Net Cash Flow From Investing Activities, Continuing | $-407.35 Million |
| Net Cash Flow From Financing Activities | $-351.48 Million |
Income Statement
September 29, 2023 to September 28, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $423.78 Million |
| Preferred Stock Dividends And Other Adjustments | $10.70 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $10.70 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $4.21 Million |
| Basic Average Shares | $102.92 Million |
| Income/Loss From Continuing Operations After Tax | $427.99 Million |
| Benefits Costs and Expenses | $3.55 Billion |
| Other Operating Expenses | $2.76 Billion |
| Selling, General, and Administrative Expenses | $752.44 Million |
| Costs And Expenses | $3.57 Billion |
| Operating Income/Loss | $527.96 Million |
| Revenues | $4.06 Billion |
| Net Income/Loss Available To Common Stockholders, Basic | $413.08 Million |
| Diluted Average Shares | $155.23 Million |
| Basic Earnings Per Share | $8.05 |
| Income/Loss From Continuing Operations Before Tax | $512.79 Million |
| Operating Expenses | $3.51 Billion |
| Net Income/Loss | $427.99 Million |
| Diluted Earnings Per Share | $8.01 |
| Income Tax Expense/Benefit | $90.62 Million |
Balance Sheet
September 29, 2023 to September 28, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $3.16 Billion |
| Inventory | $336.20 Million |
| Other Current Assets | $1.07 Billion |
| Assets | $8.00 Billion |
| Redeemable Noncontrolling Interest | $40.59 Million |
| Liabilities And Equity | $8.00 Billion |
| Current Assets | $1.49 Billion |
| Current Liabilities | $1.01 Billion |
| Temporary Equity | $40.59 Million |
| Noncurrent Assets | $6.51 Billion |
| Accounts Payable | $135.96 Million |
| Prepaid Expenses | $92.63 Million |
| Equity | $3.79 Billion |
| Other Current Liabilities | $665.18 Million |
| Wages | $211.08 Million |
| Equity Attributable To Noncontrolling Interest | $4.85 Million |
| Liabilities | $4.18 Billion |
| Equity Attributable To Parent | $3.78 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Related Companies
View additional S&P 500 companies similar to Charles River Laboratories International (CRL)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.